Evidence map›Paper›PMID 36337310›Full record

Trial reportWorld journal of clinical oncology2022

Clinical relevance of the use of Dentoxol

Sebastián Solé, Sergio Becerra, Claudia Carvajal, Piero Bettolli, Hernán Letelier, Alejandro Santini, Lorena Vargas, Alexander Cifuentes, Francisco Larsen, Natalia Jara and 5 more

Open access · diamondAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in World journal of clinical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 1 country.

Sebastián SoléDepartment of Radiotherapy, Radiomedicine Institute, Américo Vespucio Norte 1314 Vitacura, 7630370, Santiago, Chile. sebasole@gmail.com.
Sergio BecerraNational Institute of Cancer, Santiago, Servicio de Salud Metropolitano Norte, Av Profesor Zañartu 1010, Independencia, 8380455, Santiago, Chile.
Claudia CarvajalNational Institute of Cancer, Santiago, Servicio de Salud Metropolitano Norte, Av Profesor Zañartu 1010, Independencia, 8380455, Santiago, Chile.
Piero BettolliOncologic Institute Arturo López Pérez Foundation, José Manuel Infante 805, Providencia, 7500691, Santiago, Chile.
Hernán LetelierHospital Base Valdivia, Bueras 1003 s/n XIV Región, 5100238, Valdivia, Chile.
Alejandro SantiniOncologic Center of Antofagasta, Los Pumas 10255, Antofagasta, 1267348, Antofagasta, Chile.
Lorena VargasDepartment of Radiotherapy, Radiomedicine Institute, Américo Vespucio Norte 1314 Vitacura, 7630370, Santiago, Chile.
Alexander CifuentesNational Institute of Cancer, Santiago, Servicio de Salud Metropolitano Norte, Av Profesor Zañartu 1010, Independencia, 8380455, Santiago, Chile.
Francisco LarsenDepartment of Radiotherapy, Radiomedicine Institute, Américo Vespucio Norte 1314 Vitacura, 7630370, Santiago, Chile.
Natalia JaraDepartment of Radiotherapy, Radiomedicine Institute, Américo Vespucio Norte 1314 Vitacura, 7630370, Santiago, Chile.
Jorge OyarzúnHospital Base Valdivia, Bueras 1003 s/n XIV Región, 5100238, Valdivia, Chile.
Eva BustamanteOncologic Institute Arturo López Pérez Foundation, José Manuel Infante 805, Providencia, 7500691, Santiago, Chile.
Benjamín MartínezUniversidad Mayor, Santiago, Av Libertador Bernardo O´Higgins 2013, 8340585, Santiago, Chile.
David RosenbergIngalfarma, Dr Manuel Barros Borgoño 71, Oficina 1308, Providencia, 7500593, Santiago, Chile.
Tomas GalvánIngalfarma, Dr Manuel Barros Borgoño 71, Oficina 1308, Providencia, 7500593, Santiago, Chile.
Instituto de Radiomedicina · CLInstituto Nacional del Cáncer · CLFundación Arturo López Pérez · CLHospital Barros Luco-Trudeau · CLHospital Base · CLUniversidad Bernardo O'Higgins · CLUniversidad de Antofagasta · CL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSevere oral mucositis associated with cancer therapy is a frequent complication that may affect a patient's systemic condition, resulting in interruption and/or prolongation of cancer therapy. Dentoxol

aimTo describe the clinical impact of Dentoxol

methodsClinical significance was measured using the results obtained in a randomized controlled clinical trial previously conducted by the same group of researchers. The measures of clinical significance evaluated were the absolute risk or incidence, relative risk, absolute risk reduction, relative risk reduction, number needed to treat, and odds ratio.

resultsThe data obtained show that the impact of Dentoxol

conclusionThe results of this study justify the incorporation of Dentoxol

Indexed as

Clinical trialDentoxolOral mucositisPreventionRadiotherapyTreatment

Identifiers

PMID36337310
PMCPMC9630999
OpenAlexW4306784752

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.